NUVB Nuvation Bio Inc.

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index adding 0.8% and the S

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.5% and the State

Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung Cancer. The data indicated durable and consistent efficacy in advanced ROS1+ non small cell lung cancer regardless of prior chemotherapy exposure. IBTROZI efficacy was reported as consistent across different ROS1 fusion partners in patients with advanced ROS1+ non small cell lung cancer. These IBTROZI subgroup findings matter, but investors may wish to weigh them alongside...

Cramer flagged the company as too risky for most people, even as the stock climbs on real medical news.

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The bank just put a big number on a small biotech company, and the target rests on a newly launched drug.

The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IBTROZI revenue hit $23.2 million with 85% of new patient starts in first-line setting.

Nuvation Bio (NYSE:NUVB) reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, as the company said use of the ROS1-targeted lung cancer therapy continued to shift toward first-line patients. IBTROZI revenue increased 25% from the f

Moby summary of Nuvation Bio Inc.'s Q2 2026 earnings call

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +16.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Inc. announced that new long-term analyses from its pivotal Phase 2 TRUST-I and TRUST-II trials of IBTROZI (taletrectinib) in adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, originally scheduled for presentation at WCLC and ESMO in 2026, were subsequently presented and posted on its website. The upcoming detailed subgroup efficacy and safety readouts for IBTROZI, building on its June 2025 US FDA approval, give investors additional...

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Nuvation Bio's (NUVB) leadership showed "significant excitement" around the Safusidenib clinical pro

Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

According to TheFly, RBC Capital analyst Leonid Timashev said the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.

Nuvation Bio Inc. (NYSE:NUVB) is one of the best small cap stocks to buy with the highest upside potential. RBC Capital lowered the price target on Nuvation Bio Inc. (NYSE:NUVB) to $19 from $20 on July 7 and reaffirmed an Outperform rating on the shares. The rating update came as part of a broader research note […]

Nuvation Bio Inc (NYSE:NUVB) is one of billionaire David Abrams’ top stock picks with upside potential. Nuvation Bio shares gained nearly 170% over the past year, and analysts project a more than 150% upside for the stock over the next 12 months. Some 41 hedge funds are backing Nuvation Bio stock. This comes as Nuvation […]